Neurofeedback Research

This systematic review and meta-analysis, published in JAMA Psychiatry by the European ADHD Guidelines Group, evaluated the efficacy of neurofeedback for treating ADHD by analyzing 38 randomized clinical trials encompassing 2,472 participants aged 5 to 40 years. The study focused specifically on probably-blinded outcome assessments — reports from individuals judged to be unaware of treatment allocation — to reduce placebo and expectation bias.

The primary analysis found no significant improvement in ADHD total symptoms when assessed by probably-blinded raters (SMD = 0.04, 95% CI: -0.10 to 0.18). However, a subgroup analysis restricted to RCTs using established standard neurofeedback protocols (such as theta/beta ratio or sensorimotor rhythm training) showed a small but statistically significant effect (SMD = 0.21, 95% CI: 0.02 to 0.40). Among five neuropsychological outcomes analyzed, only processing speed showed a significant improvement (SMD = 0.35).

The authors conclude that neurofeedback does not appear to meaningfully benefit individuals with ADHD at the group level, and suggest that future research should focus on identifying specific patient subgroups who may respond, using standard protocols, and leveraging precision medicine approaches.

This comprehensive meta-analysis evaluated the efficacy of neurofeedback as a non-pharmacological treatment for major depressive disorders. The researchers analyzed 22 studies examining the effects of neurofeedback interventions on depression symptoms, neurophysiological outcomes, and neuropsychological function, calculating Hedges' g effect sizes and exploring moderators such as intervention settings, study designs, and participant demographics.

The analysis revealed significant effects of neurofeedback on depression symptoms (Hedges' g = -0.600), neurophysiological outcomes (Hedges' g = -0.726), and a moderate effect on neuropsychological function (Hedges' g = -0.418). Moderator analysis showed that longer intervention durations were associated with greater improvements in depressive symptoms and neuropsychological function, while shorter individual sessions were linked to better neurophysiological outcomes.

The authors conclude that neurofeedback holds promising potential as a non-invasive, non-pharmacological intervention for improving depressive symptoms and associated neurological outcomes in individuals with major depressive disorders.

This systematic review and multilevel meta-analysis examined whether combining cognitive training with neurofeedback (CTNF) improves cognitive function in healthy adults beyond cognitive training alone. The researchers searched PubMed, Scopus, PsycINFO, and MEDLINE for intervention studies using this combined approach.

From an initial screening of 234 records, four studies met inclusion criteria — three using near-infrared spectroscopy (NIRS) and one using electroencephalography (EEG). The multilevel meta-analysis was conducted on the three NIRS studies, which included 166 participants with mean ages ranging from 21 to 66 years. The analysis revealed that CTNF had beneficial effects on episodic memory, long-term memory, and working memory domains.

Although the evidence base was limited to only three studies in the quantitative analysis, the results suggest that combining cognitive training with NIRS-based neurofeedback may enhance memory functioning in healthy adults, supporting the idea that real-time brain signal feedback can augment traditional cognitive training approaches.

This meta-analysis specifically examined the long-term sustainability of neurofeedback effects in ADHD, addressing a key question about whether benefits persist after treatment ends.

Analyzing follow-up data from multiple controlled trials, the study found that neurofeedback effects are maintained at 6-12 month follow-up, and in some cases continue to improve. This contrasts with medication, which only works while being taken. The findings suggest neurofeedback produces lasting brain changes rather than temporary symptomatic relief.

John Gruzelier's comprehensive review examines the application of neurofeedback for peak performance enhancement in healthy individuals. The review covers applications in music, dance, acting, sports, and cognitive tasks.

Key findings include improved musical performance in conservatory students (both technical execution and emotional expression), enhanced microsurgical skills, and improved athletic performance. The mechanisms appear to involve improved attentional control and anxiety regulation.

D. Corydon Hammond's extensive review provides an updated overview of neurofeedback applications across multiple clinical conditions. The review synthesizes decades of research establishing neurofeedback as an evidence-based intervention.

Key findings include strong evidence for ADHD treatment, promising results for anxiety and depression, and emerging applications for PTSD, traumatic brain injury, and autism spectrum disorders. The review emphasizes that effects tend to be lasting, unlike medication effects that cease when treatment stops.

This landmark meta-analysis examined 15 controlled studies of neurofeedback for ADHD, finding significant effects across all three core symptom domains. The analysis established neurofeedback as an evidence-based treatment for ADHD.

Effect sizes were large for inattention (ES=0.81) and impulsivity (ES=0.69), and medium for hyperactivity (ES=0.40). These effects are comparable to those found in medication studies, supporting neurofeedback as a viable treatment alternative.